Raptor Falls On Failed Investigator-Run NASH Study
This article was originally published in Scrip
Raptor Pharmaceuticals fell 37.5% on Sept. 14 to $7.52 per share after the Novato, California-based company revealed that RP103, a delayed-release version of its approved cystinosis drug Procysbi (cysteamine bitartrate) failed in a Phase IIb pediatric non-alcoholic steatohepatitis (NASH) clinical trial.
You may also be interested in...
Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.